Toralizumab

This article is about a drug. For other uses, see IDEC.

Toralizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD40 ligand
Identifiers
CAS Number	252662-47-8 N
ATC code	none
KEGG	D06193 Y
Chemical data
Molecular mass	148,426 Daltons
NY (what is this?)  (verify)

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).

In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.

The drug was developed by IDEC Pharmaceuticals Corporation.